Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Licenses Rosetta Inpharmatics siRNA Informatics Technology

NEW YORK, May 24 (GenomeWeb News) - Sigma-Aldrich has gained an exclusive license to Rosetta Inpharmatics' bioinformatics design tools for siRNA research and development purposes, Rosetta said today.

 

Sigma- Aldrich said it plans to use Rosetta' design technology to launch human and model organism siRNA whole-genome libraries, to deliver siRNA panels targeted to specific gene families, and to provide access to single-target pre-designed siRNAs through an enhanced Web interface on its website.

 

Rosetta is a wholly owned subsidiary of Merck.

 

Financial details were not discussed.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.